Compatibility studies of raw materials, excipients, and packaging materials are fundamental to ensuring that a pharmaceutical product maintains its identity, strength, quality, and purity throughout its shelf life. Protheragen delivers end-to-end compatibility evaluation services tailored for both preclinical research and IIT clinical studies, helping developers de-risk formulation and packaging choices early in the radiopharmaceutical lifecycle.
Compatibility Testing for Conventional and Radiopharmaceuticals
Compatibility testing is a multidisciplinary investigation designed to detect any undesirable physical, chemical, or biological interactions between an active pharmaceutical ingredient (API), functional excipients, and the container closure system. For conventional pharmaceuticals, these studies focus on issues such as pH shifts, precipitation, or leachables from rubber stoppers and glass vials. The objective is to confirm that the chosen combination of components does not compromise stability, efficacy, or patient safety over the intended storage period.
Fig 1. A scheme for the pre-formulation parameters to develop solid dosage forms. (Mishra, Anoop, et al., 2023)
In the context of radiopharmaceuticals, the complexity increases substantially. Radiation emitted by the isotope can induce radiolysis of both the drug substance and the surrounding matrix, generating free radicals that accelerate degradation. Additionally, many radiopharmaceuticals are administered parenterally and therefore require sterile, pyrogen-free container closure systems that must also act as radiation shields. Regulatory agencies expect documented evidence that the packaging materials do not adsorb the radioactive dose, alter radiochemical purity, or permit leakage of volatile or ionizing components during transport, storage, or clinical use.
Our Services
Protheragen delivers a full-spectrum integrated compatibility study program, covering early-stage raw material screening all the way to systematic container closure system verification. Our team tailors customized study designs to tackle the unique technical challenges of radiopharmaceuticals, including radiolytic degradation, short half-life characteristics, and strict sterility standards. This comprehensive solution consistently maintains the stability and safety of radiotracer products throughout manufacturing, storage, and clinical administration processes.
Our Services
Raw Material & Excipient Compatibility Screening
- Evaluate chemical interactions between API and candidate excipients.
- Assess impact of antioxidants, buffers, and radioprotective agents on stability.
- Perform forced-degradation studies under thermal, oxidative, and radiolytic stress.
Container Closure System Suitability
- Conduct material property characterization for vials, rubber stoppers, sealing components and prefilled syringes.
- Validate packaging barrier performance against light exposure, moisture ingress, oxygen penetration and solvent volatilization.
Extractables & Leachables Studies
- Generate extraction profiles for plastics, elastomers, and coatings.
- Conduct toxicological risk assessments based on patient exposure limits.
- Compare batch-to-batch consistency of extractable profiles.
Container Closure Integrity Testing (CCIT)
- Vacuum decay testing for non-destructive leak detection.
- Helium leak detection for high-sensitivity seal verification.
- Microbial ingress and dye ingress testing to validate sterility assurance.
Radiopharmaceutical-Specific Compatibility
- Validate compatibility with lead, tungsten, or composite shielding.
- Assess adsorption of radioactivity onto vial/stopper surfaces.
- Evaluate in-use stability of radiolabeled kits under worst-case conditions.
Stability & Regulatory Documentation
- Develop stability test protocols covering diverse drug concentrations and packaging container specifications.
- Compile comprehensive chemical and manufacturing technical dossiers detailing product formulation, stability performance and container matching data.
- Generate technical risk evaluation reports and explanatory documents for production process and packaging adjustments.
Why Choose Protheragen?
Protheragen combines deep radiopharmaceutical expertise with rigorous pharmaceutical research capabilities to deliver defensible compatibility data.
- Radiopharmaceutical Focus: We fully account for distinctive factors including radiolytic degradation, short radioactive half-lives and radiation shielding needs that influence packaging and excipient compatibility test results.
- Standardized Study Design: Every trial is structured around mature technical specifications for container closure evaluation and excipient compatibility assessment.
- Integrated Service Model: We deliver continuous one-stop technical support ranging from initial raw material screening to finalized technical document collation under unified quality management standards.
- Advanced Testing Capabilities: Our laboratory performs vacuum decay testing, helium leak detection, microbial barrier assessment and comprehensive physicochemical characterization for plastic and rubber packaging materials.
- Risk-Based Approach: High-risk material and formulation interactions are identified and evaluated at the early research stage to cut overall cycle costs and guarantee product safety during use.
- Rapid Turnaround: Custom test schedules are formulated to match the tight development schedules common to PET radiotracer and alpha-emitting therapeutic radiopharmaceutical projects.
Contact Us
Whether you are preparing an IND, launching an IIT study, or managing a post-approval packaging change, Protheragen's compatibility team is ready to support your program. Please contact us or reach out to our business development team to discuss your specific raw material, excipient, or packaging material compatibility needs.
Reference
- Mishra, Anoop, et al. "Molecular and qualitative characterization of compatibility between valacyclovir hydrochloride and excipients as raw materials for the development of solid oral dosage formulation." American Journal of Biopharmacy and Pharmaceutical Sciences 3 (2023).
